Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Bangiyeva, Valentina ^a   Rosenbloom, Ava ^a   Alexander, Ashlynn E ^a   Isanova, Bella ^a   Popko, Timothy ^a   Schoenfeld, Alan R ^a  

^a ADELPHI UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA5 INTEGRIN; CYCLIN D1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MUTANT PROTEIN; PROTEIN P27; PROTEIN ZO1; VON HIPPEL LINDAU PROTEIN; CYCLOHEXIMIDE; PROTEIN SYNTHESIS INHIBITOR; UBIQUITIN; VHL PROTEIN, HUMAN;

ARTICLE; CANCER RISK; CELL FUNCTION; CELL LEVEL; CELL STRUCTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE CLASSIFICATION; EPITHELIUM CELL; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC STABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; TIGHT JUNCTION; VON HIPPEL LINDAU DISEASE; WILD TYPE; BIOLOGICAL MODEL; BIOSYNTHESIS; CARCINOMA; CELL LINE; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; KIDNEY TUMOR; METABOLISM; MUTATION; PHENOTYPE;

CARCINOMA; CELL LINE; CYCLOHEXIMIDE; GENE EXPRESSION REGULATION; GENOTYPE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; MODELS, BIOLOGICAL; MUTATION; PHENOTYPE; PROTEIN SYNTHESIS INHIBITORS; TIGHT JUNCTIONS; UBIQUITIN; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 68949199658     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-229     Document Type: Article

References (93)

1. Maher ER Iselius L Yates JR Littler M Benjamin C Harris R Sampson J Williams A Ferguson SMA Morton N Von Hippel-Lindau disease: A genetic study J Med Genet 1991, 28(7):443-447. 1016952 1895313 10.1136/ jmg.28.7.443
2. Kim WY Kaelin WG Role of VHL gene mutation in human cancer J Clin Oncol 2004, 22(24):4991-5004. 10.1200/JCO.2004.05.061 15611513
3. Latif F Tory K Gnarra J Yao M Duh FM Orcutt ML Stackhouse T Kuzmin I Modi W Geil L et al Identification of the von Hippel-Lindau disease tumor suppressor gene Science 1993, 260(5112):1317-1320. 10.1126/ science.8493574 8493574
4. Gnarra JR Tory K Weng Y Schmidt L Wei MH Li H Latif F Liu S Chen F Duh FM et al Mutations of the VHL tumour suppressor gene in renal carcinoma Nat Genet 1994, 7(1):85-90. 10.1038/ng0594-85 7915601
5. Whaley JM Naglich J Gelbert L Hsia YE Lamiell JM Green JS Collins D Neumann HP Laidlaw J Li FP et al Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma Am J Hum Genet 1994, 55(6):1092-1102. 1918449 7977367
6. Shuin T Kondo K Torigoe S Kishida T Kubota Y Hosaka M Nagashima Y Kitamura H Latif F Zbar B et al Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas Cancer Res 1994, 54:2852-2855. 8187067
7. Foster K Prowse A Berg van den A Fleming S Hulsbeek MM Crossey PA Richards FM Cairns P Affara NA Ferguson-Smith MA et al Somatic mutations of the von Hippel-Lindau disease tumor suppressor gene in non-familial clear cell renal carcinoma Hum Mol Genet 1994, 3:2169-2173. 10.1093/hmg/ 3.12.2169 7881415
8. Lee JY Dong SM Park WS Yoo NJ Kim CS Jang JJ Chi JG Zbar B Lubensky IA Linehan WM et al Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas Cancer Res 1998, 58(3):504-508. 9458097
9. Maher ER Kaelin WG Jr von Hippel-Lindau disease Medicine (Baltimore) 1997, 76(6):381-391. 10.1097/00005792-199711000-00001 9413424
10. Kaelin WG Jr Molecular basis of the VHL hereditary cancer syndrome Nat Rev Cancer 2002, 2(9):673-682. 10.1038/nrc885 12209156
11. Schoenfeld A Davidowitz EJ Burk RD A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor Proc Natl Acad Sci USA 1998, 95(15):8817-8822. 21160 9671762 10.1073/pnas.95.15.8817
12. Iliopoulos O Ohh M Kaelin WG Jr pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation Proc Natl Acad Sci USA 1998, 95(20):11661-11666. 21697 9751722 10.1073/pnas.95.20.11661
13. Blankenship C Naglich JG Whaley JM Seizinger B Kley N Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity Oncogene 1999, 18(8):1529-1535. 10.1038/sj.onc.1202473 10102622
14. Kibel A Iliopoulos O DeCaprio JA Kaelin WG Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C Science 1995, 269:1444-1446. 10.1126/science.7660130 7660130
15. Pause A Lee S Worrell RA Chen DY Burgess WH Linehan WM Klausner RD The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins Proc Natl Acad Sci USA 1997, 94(6):2156-2161. 20057 9122164 10.1073/pnas.94.6.2156
16. Lonergan KM Iliopoulos O Ohh M Kamura T Conaway RC Conaway JW Kaelin WG Jr Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2 Mol Cell Biol 1998, 18(2):732-741. 108784 9447969
17. Kamura T Koepp DM Conrad MN Skowyra D Moreland RJ Iliopoulos O Lane WS Kaelin WG Jr Elledge SJ Conaway RC et al Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase Science 1999, 284(5414):657-661. 10.1126/science.284.5414.657 10213691
18. Iwai K Yamanaka K Kamura T Minato N Conaway RC Conaway JW Klausner RD Pause A Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex Proc Natl Acad Sci USA 1999, 96(22):12436-12441. 22941 10535940 10.1073/pnas.96.22.12436
19. Lisztwan J Imbert G Wirbelauer C Gstaiger M Krek W The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity Genes Dev 1999, 13:1822-1833. 316884 10421634 10.1101/ gad.13.14.1822
20. Maxwell PH Wiesener MS Chang GW Clifford SC Vaux EC Cockman ME Wykoff CC Pugh CW Maher ER Ratcliffe PJ The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature 1999, 399(6733):271-275. 10.1038/20459 10353251
21. Tanimoto K Makino Y Pereira T Poellinger L Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein Embo J 2000, 19(16):4298-4309. 302039 10944113 10.1093/emboj/19.16.4298
22. Cockman ME Masson N Mole DR Jaakkola P Chang GW Clifford SC Maher ER Pugh CW Ratcliffe PJ Maxwell PH Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein J Biol Chem 2000, 275(33):25733-25741. 10.1074/jbc.M002740200 10823831
23. Ohh M Park CW Ivan M Hoffman MA Kim TY Huang LE Pavletich N Chau V Kaelin WG Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein Nat Cell Biol 2000, 2(7):423-427. 10.1038/35017054 10878807
24. Sufan RI Jewett MA Ohh M The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma Am J Physiol Renal Physiol 2004, 287(1):F1-6. 10.1152/ajprenal.00424.2003 15180922
25. Ivan M Kondo K Yang H Kim W Valiando J Ohh M Salic A Asara JM Lane WS Kaelin WG Jr HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing Science 2001, 292(5516):464-468. 10.1126/science.1059817 11292862
26. Jaakkola P Mole DR Tian YM Wilson MI Gielbert J Gaskell SJ Kriegsheim A Hebestreit HF Mukherji M Schofield CJ et al Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation Science 2001, 292(5516):468-472. 10.1126/science.1059796 11292861
27. Yu F White SB Zhao Q Lee FS HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation Proc Natl Acad Sci USA 2001, 98(17):9630-9635. 55503 11504942 10.1073/pnas.181341498
28. Zbar B Kishida T Chen F Schmidt L Maher ER Richards FM Crossey PA Webster AR Affara NA Ferguson-Smith MA et al Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan Hum Mutat 1996, 8(4):348-357. 10.1002/ (SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3 8956040
29. Chen F Kishida T Yao M Hustad T Glavac D Dean M Gnarra JR Orcutt ML Duh FM Glenn G et al Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype Hum Mutat 1995, 5(1):66-75. 10.1002/humu.1380050109 7728151
30. Clifford SC Cockman ME Smallwood AC Mole DR Woodward ER Maxwell PH Ratcliffe PJ Maher ER et al Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease Hum Mol Genet 2001, 10(10):1029-1038. 10.1093/hmg/10.10.1029 11331613
31. Hoffman MA Ohh M Yang H Klco JM Ivan M Kaelin WG Jr von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF Hum Mol Genet 2001, 10(10):1019-1027. 10.1093/hmg/ 10.10.1019 11331612
32. Knauth K Bex C Jemth P Buchberger A Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions Oncogene 2006, 25(3):370-377. 16261165
33. Lee S Nakamura E Yang H Wei W Linggi MS Sajan MP Farese RV Freeman RS Carter BD Kaelin WG Jr et al Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer Cancer Cell 2005, 8(2):155-167. 10.1016/j.ccr.2005.06.015 16098468
34. Li L Zhang L Zhang X Yan Q Minamishima YA Olumi AF Mao M Bartz S Kaelin WG Jr Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations Mol Cell Biol 2007, 27(15):5381-5392. 1952077 17526729 10.1128/MCB.00282-07
35. Kondo K Kim WY Lechpammer M Kaelin WG Jr Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth PLoS Biol 2003, 1(3):E83. 300692 14691554 10.1371/journal.pbio.0000083
36. Kondo K Klco J Nakamura E Lechpammer M Kaelin WG Jr Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein Cancer Cell 2002, 1(3):237-246. 10.1016/S1535-6108(02)00043-0 12086860
37. Zimmer M Doucette D Siddiqui N Iliopoulos O Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors Mol Cancer Res 2004, 2(2):89-95. 14985465
38. Kim WY Safran M Buckley MR Ebert BL Glickman J Bosenberg M Regan M Kaelin WG Jr Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo Embo J 2006, 25(19):4650-4662. 1589988 16977322 10.1038/sj.emboj.7601300
39. Davidowitz EJ Schoenfeld AR Burk RD VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling Mol Cell Biol 2001, 21(3):865-874. 86677 11154273 10.1128/MCB.21.3.865-874.2001
40. Lieubeau-Teillet B Rak J Jothy S Iliopoulos O Kaelin W Kerbel RS von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids Cancer Res 1998, 58(21):4957-4962. 9810005
41. Ohh M Yauch RL Lonergan KM Whaley JM Stemmer-Rachamimov AO Louis DN Gavin BJ Kley N Kaelin WG Jr Iliopoulos O The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix Mol Cell 1998, 1(7):959-968. 10.1016/ S1097-2765(00)80096-9 9651579
42. Esteban-Barragan MA Avila P Alvarez-Tejado M Gutierrez MD Garcia-Pardo A Sanchez-Madrid F Landazuri MO Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions Cancer Res 2002, 62(10):2929-2936. 12019174
43. Hergovich A Lisztwan J Barry R Ballschmieter P Krek W Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL Nat Cell Biol 2003, 5(1):64-70. 10.1038/ncb899 12510195
44. Calzada MJ Esteban MA Feijoo-Cuaresma M Castellanos MC Naranjo-Suarez S Temes E Mendez F Yanez-Mo M Ohh M Landazuri MO von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms Cancer Res 2006, 66(3):1553-1560. 10.1158/ 0008-5472.CAN-05-3236 16452212
45. Lutz MS Burk RD Primary cilium formation requires von hippel-lindau gene function in renal-derived cells Cancer Res 2006, 66(14):6903-6907. 10.1158/0008-5472.CAN-06-0501 16849532
46. Esteban MA Harten SK Tran MG Maxwell PH Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein J Am Soc Nephrol 2006, 17(7):1801-1806. 10.1681/ ASN.2006020181 16775032
47. Hughes MD Kapllani E Alexander AE Burk RD Schoenfeld AR HIF-2alpha downregulation in the absence of functional VHL is not sufficient for renal cell differentiation Cancer Cell Int 2007, 7:13. 1919349 17598890 10.1186/1475-2867-7-13
48. Ji Q Burk RD Downregulation of integrins by von Hippel-Lindau (VHL) tumor suppressor protein is independent of VHL-directed hypoxia-inducible factor alpha degradation Biochem Cell Biol 2008, 86(3):227-234. 10.1139/O08-035 18523483
49. Turcotte S Chan DA Sutphin PD Hay MP Denny WA Giaccia AJ A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy Cancer Cell 2008, 14(1):90-102. 10.1016/j.ccr.2008.06.004 18598947
50. Esteban MA Tran MG Harten SK Hill P Castellanos MC Chandra A Raval R O'Brien TS Maxwell PH Regulation of E-cadherin expression by VHL and hypoxia-inducible factor Cancer Res 2006, 66(7):3567-3575. 10.1158/ 0008-5472.CAN-05-2670 16585181
51. Higgins DF Kimura K Bernhardt WM Shrimanker N Akai Y Hohenstein B Saito Y Johnson RS Kretzler M Cohen CD et al Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition J Clin Invest 2007, 117(12):3810-3820. 2082142 18037992
52. Ausubel FM Brent R Kingston RE Moore DD Seidman JG Smith JA Struhl K eds Current Protocols in Molecular Biology New York: John Wiley and Sons 1994.
53. Schoenfeld AR Davidowitz EJ Burk RD Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products Proc Natl Acad Sci USA 2000, 97(15):8507-8512. 26978 10900011 10.1073/ pnas.97.15.8507
54. Schoenfeld AR Apgar S Dolios G Wang R Aaronson SA BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cellular response to DNA damage Mol Cell Biol 2004, 24(17):7444-7455. 506974 15314155 10.1128/ MCB.24.17.7444-7455.2004
55. Brummelkamp TR Bernards R Agami R Stable suppression of tumorigenicity by virus-mediated RNA interference Cancer Cell 2002, 2(3):243-247. 10.1016/S1535-6108(02)00122-8 12242156
56. Naviaux RK Costanzi E Haas M Verma IM The pCL vector system: Rapid production of helper-free, high-titer, recombinant retroviruses J Virol 1996, 70(8):5701-5705. 190538 8764092
57. Béroud C Joly D Gallou C Staroz F Orfanelli MT Junien C Software and database for the analysis of mutations in the VHL gene Nucleic Acids Res 1998, 26(1):258-260.
58. Crossey PA Richards FM Foster K Green JS Prowse A Latif F Lerman MI Zbar B Affara NA Ferguson-Smith MA et al Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype Hum Mol Genet 1994, 3:1303-1308. 10.1093/hmg/3.8.1303 7987306
59. Stolle C Glenn G Zbar B Humphrey JS Choyke P Walther M Pack S Hurley K Andrey C Klausner R et al Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene Hum Mutat 1998, 12(6):417-423. 10.1002/ (SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K 9829911
60. Brauch H Kishida T Glavac D Chen F Pausch F Hofler H Latif F Lerman MI Zbar B Neumann HP Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: Evidence for a founder effect Hum Genet 1995, 95(5):551-556. 10.1007/BF00223868 7759077
61. Glavac D Neumann HP Wittke C Jaenig H Masek O Streicher T Pausch F Engelhardt D Plate KH Hofler H et al Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe Hum Genet 1996, 98(3):271-280. 10.1007/s004390050206 8707293
62. Chen F Slife L Kishida T Mulvihill J Tisherman SE Zbar B Genotype-phenotype correlation in von Hippel-Lindau disease: identification of a mutation associated with VHL type 2A J Med Genet 1996, 33(8):716-717. 1050712 8863170 10.1136/jmg.33.8.716
63. Bradley JF Collins DL Schimke RN Parrott HN Rothberg PG Two distinct phenotypes caused by two different missense mutations in the same codon of the VHL gene Am J Med Genet 1999, 87(2):163-167. 10.1002/ (SICI)1096-8628(19991119)87:2<163::AID-AJMG7>3.0.CO;2-A 10533030
64. Olschwang S Richard S Boisson C Giraud S Laurent-Puig P Resche F Thomas G Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma Hum Mutat 1998, 12(6):424-430. 10.1002/ (SICI)1098-1004(1998)12:6<424::AID-HUMU9>3.0.CO;2-H 9829912
65. Wu Y Nishio H Lee MJ Ayaki H Hayashi A Ooba T Ogawa T Sumino K et al Molecular genetic analysis and mutation screening of the VHL gene in a Japanese family with von Hippel-Lindau disease Kobe J Med Sci 2000, 46(4):147-153. 11354926
66. Crossey PA Foster K Richards FM Phipps ME Latif F Tory K Jones MH Bentley E Kumar R Lerman MI et al Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: Analysis of allele loss in VHL tumours Hum Genet 1994, 93(1):53-58. 10.1007/ BF00218913 8270255
67. Ritter MM Frilling A Crossey PA Hoppner W Maher ER Mulligan L Ponder BA Engelhardt D Isolated familial pheochromocytoma as a variant of von Hippel-Lindau disease J Clin Endocrinol Metab 1996, 81(3):1035-1037. 10.1210/jc.81.3.1035 8772572
68. Bindra RS Vasselli JR Stearman R Linehan WM Klausner RD VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells Cancer Res 2002, 62(11):3014-3019. 12036906
69. Zatyka M da Silva NF Clifford SC Morris MR Wiesener MS Eckardt KU Houlston RS Richards FM Latif F Maher ER Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease Cancer Res 2002, 62(13):3803-3811. 12097293
70. Pause A Lee S Lonergan KM Klausner RD The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal Proc Natl Acad Sci USA 1998, 95(3):993-998. 18649 9448273 10.1073/ pnas.95.3.993
71. Schoenfeld AR Parris T Eisenberger A Davidowitz EJ De Leon M Talasazan F Devarajan P Burk RD The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis Oncogene 2000, 19(51):5851-5857. 10.1038/sj.onc.1203985 11127815
72. Moustakas A Heldin CH Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression Cancer Sci 2007, 98(10):1512-1520. 10.1111/j.1349-7006.2007.00550.x 17645776
73. Evans AJ Russell RC Roche O Burry TN Fish JE Chow VW Kim WY Saravanan A Maynard MA Gervais ML et al VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail Mol Cell Biol 2007, 27(1):157-169. 1800649 17060462 10.1128/MCB.00892-06
74. Harten SK Shukla D Barod R Hergovich A Balda MS Matter K Esteban MA Maxwell PH Regulation of renal epithelial tight junctions by the von Hippel-Lindau tumor suppressor gene involves occludin and claudin 1 and is independent of E-cadherin Mol Biol Cell 2009, 20(3):1089-1101. 2633394 19073886 10.1091/mbc.E08-06-0566
75. Ramaswamy S Nakamura N Vazquez F Batt DB Perera S Roberts TM Sellers WR Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway Proc Natl Acad Sci USA 1999, 96(5):2110-2115. 26745 10051603 10.1073/ pnas.96.5.2110
76. Bojarski C Weiske J Schoneberg T Schroder W Mankertz J Schulzke JD Florian P Fromm M Tauber R Huber O The specific fates of tight junction proteins in apoptotic epithelial cells J Cell Sci 2004, 117(Pt 10):2097-2107 10.1242/jcs.01071 15054114
77. Gorospe M Egan JM Zbar B Lerman M Geil L Kuzmin I Holbrook NJ Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells Mol Cell Biol 1999, 19(2):1289-1300. 116058 9891063
78. Raval RR Lau KW Tran MG Sowter HM Mandriota SJ Li JL Pugh CW Maxwell PH Harris AL Ratcliffe PJ Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma Mol Cell Biol 2005, 25(13):5675-5686. 1157001 15964822 10.1128/ MCB.25.13.5675-5686.2005
79. Rankin EB Tomaszewski JE Haase VH Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor Cancer Res 2006, 66(5):2576-2583. 10.1158/0008-5472.CAN-05-3241 16510575
80. Young AP Schlisio S Minamishima YA Zhang Q Li L Grisanzio C Signoretti S Kaelin WG Jr VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400 Nat Cell Biol 2008, 10(3):361-369. 10.1038/ ncb1699 18297059
81. Tsihlias J Kapusta L Slingerland J The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer Annu Rev Med 1999, 50:401-423. 10.1146/annurev.med.50.1.401 10073286
82. Slingerland J Pagano M Regulation of the cdk inhibitor p27 and its deregulation in cancer J Cell Physiol 2000, 183(1):10-17. 10.1002/ (SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I 10699961
83. Sicinski P Zacharek S Kim C Duality of p27Kip1 function in tumorigenesis Genes Dev 2007, 21(14):1703-1706. 10.1101/gad.1583207 17639075
84. Stebbins CE Kaelin WG Jr Pavletich NP Structure of the VHL-ElonginC-ElonginB complex: Implications for VHL tumor suppressor function Science 1999, 284(5413):455-461. 10.1126/science.284.5413.455 10205047
85. Feldman DE Thulasiraman V Ferreyra RG Frydman J Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC Mol Cell 1999, 4(6):1051-1061. 10.1016/S1097-2765(00)80233-6 10635329
86. Lee CM Hickey MM Sanford CA McGuire CG Cowey CL Simon MC Rathmell WK VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo Oncogene 2009, 28(14):1694-1705. 10.1038/onc.2009.12 19252526
87. Okuda H Hirai S Takaki Y Kamada M Baba M Sakai N Kishida T Kaneko S Yao M Ohno S et al Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes Biochem Biophys Res Commun 1999, 263(2):491-497. 10.1006/bbrc.1999.1347 10491320
88. Suzuki A Yamanaka T Hirose T Manabe N Mizuno K Shimizu M Akimoto K Izumi Y Ohnishi T Ohno S Atypical protein kinase C is involved in the evolutionarily conserved par protein complex and plays a critical role in establishing epithelia-specific junctional structures J Cell Biol 2001, 152(6):1183-1196. 2199212 11257119 10.1083/jcb.152.6.1183
89. Xu J Clark RA A three-dimensional collagen lattice induces protein kinase C-zeta activity: Role in alpha2 integrin and collagenase mRNA expression J Cell Biol 1997, 136(2):473-483. 2134818 9015316 10.1083/ jcb.136.2.473
90. Laudanna C Mochly-Rosen D Liron T Constantin G Butcher EC Evidence of zeta protein kinase C involvement in polymorphonuclear neutrophil integrin-dependent adhesion and chemotaxis J Biol Chem 1998, 273(46):30306-30315. 10.1074/jbc.273.46.30306 9804792
91. Guo W Giancotti FG Integrin signalling during tumour progression Nat Rev Mol Cell Biol 2004, 5(10):816-826. 10.1038/nrm1490 15459662
92. Paraf F Chauveau D Chretien Y Richard S Grunfeld JP Droz D Renal lesions in von Hippel-Lindau disease: Immunohistochemical expression of nephron differentiation molecules, adhesion molecules and apoptosis proteins Histopathology 2000, 36(5):457-465. 10.1046/j.1365-2559.2000.00857.x 10792488
93. Bluyssen HA Lolkema MP van Beest M Boone M Snijckers CM Los M Gebbink MF Braam B Holstege FC Giles RH et al Fibronectin is a hypoxia-independent target of the tumor suppressor VHL FEBS Lett 2004, 556(1-3):137-142. 10.1016/S0014-5793(03)01392-9 14706840